In addition, previous studies showed that combining therapies can maximize the immune response as shown for various treatment regimens for ovarian cancer, such as immune check point inhibitors, anti-angiogenic VEGF antibody and poly (ADP-ribose) polymerase inhibitor (41–45). The gene discussed is VEGFA; the disease is ovarian carcinoma.